The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B
Open accessAbstract
In a phase I study, administration of an AAV2-FIX vector into the skeletal muscle of eight hemophilia B subjects proved safe and achieved local gene transfer and FIX expression for at least 10 months after vector injection, the last time point assessed by muscle biopsy. In hemophilia B dogs we have demonstrated FIX in both muscle biopsies and circulation >4 years following AAV2-FIX injection. Because circulating FIX levels remained less than 1% of normal in human subjects from the study, the duration of AAV2-mediated transgene expression in humans is unknown. We sought to determine if FIX gene transfer and expression persisted locally at injection sites. Muscle biopsies were obtained from one subject 3.7 years following treatment and revealed transgene FIX DNA and protein by quantitative PCR, DNA fluorescence in situ hybridization, and immunohistochemistry for FIX. These results demonstrate, for the first time, multiyear FIX expression by AAV2 vector in humans and suggest that improved muscle delivery provides effective treatment for protein deficiencies or muscle-specific diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citation
Cited by
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationJessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H., & Hajjar, R. J. (2011) · Circulation · doi:10.1161/circulationaha.111.022889 · Cited by 760
Simonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
Self-citationAntibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Jaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K. M., & Hajjar, R. J. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.01.013 · Cited by 457
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citationMcIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278
Self-citationNiemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Self-citationProgress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246
Li, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
Gene therapy for severe combined immunodeficiency: are we there yet?
Cavazzana-Calvo, M., & Fischer, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30953 · Cited by 183
Carpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165
Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288001 · Cited by 157
Self-citationCashman, S. M., Ramo, K., & Kumar-Singh, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019078 · Cited by 118
Cao, O., Hoffman, B. E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C., High, K. A., & Herzog, R. W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.159 · Cited by 92
Self-citationByrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr174 · Cited by 91
Production of recombinant adeno-associated viral vectors for in vitro and in vivo use
Choi, V. W., Asokan, A., Haberman, R. A., & Samulski, R. J. (2007) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1625s78 · Cited by 52
Martino, A. T., Nayak, S., Hoffman, B. E., Cooper, M., Liao, G., Markusic, D. M., Byrne, B. J., Terhorst, C., & Herzog, R. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006376 · Cited by 54
Wang, Y.-J., Gao, C.-Y., Yang, M., Liu, X.-H., Sun, Y., Pollard, A., Dong, X.-Y., Wu, X.-B., Zhong, J.-H., Zhou, H.-D., et al. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.05.010 · Cited by 41
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
Self-citationGene therapy in an era of emerging treatment options for hemophilia B
Monahan, P. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12957 · Cited by 31
Advances in Overcoming Immune Responses following Hemophilia Gene Therapy
H. Miao, C. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-007 · Cited by 15
Metadata
- Authors
- Jiang, H., Pierce, G. F., Ozelo, M. C., de Paula, E. V., Vargas, J. A., Smith, P., Sommer, J., Luk, A., Manno, C. S., High, K. A., & Arruda, V. R.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 14
- Issue
- 3
- Pages
- 452-455
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2065451039
- Cited by
- 207
- References
- 2
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.